Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice
Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant physical and psychological detriment to patients. As of 2019, 463 million people are estimated to be living with DM worldwide, out of which 90% have type-2 diabetes mellitus (T2DM). Over the years, si...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/20420188211042145 |
| _version_ | 1818642422298574848 |
|---|---|
| author | Najeeb Shah Mohammed Altigani Abdalla Harshal Deshmukh Thozhukat Sathyapalan |
| author_facet | Najeeb Shah Mohammed Altigani Abdalla Harshal Deshmukh Thozhukat Sathyapalan |
| author_sort | Najeeb Shah |
| collection | DOAJ |
| description | Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant physical and psychological detriment to patients. As of 2019, 463 million people are estimated to be living with DM worldwide, out of which 90% have type-2 diabetes mellitus (T2DM). Over the years, significant progress has been made in identifying the risk factors for developing T2DM, understanding its pathophysiology and uncovering various metabolic pathways implicated in the disease process. This has culminated in the implementation of robust prevention programmes and the development of effective pharmacological agents, which have had a favourable impact on the management of T2DM in recent times. Despite these advances, the incidence and prevalence of T2DM continue to rise. Continuing research in improving efficacy, potency, delivery and reducing the adverse effect profile of currently available formulations is required to keep pace with this growing health challenge. Moreover, new metabolic pathways need to be targeted to produce novel pharmacotherapy to restore glucose homeostasis and address metabolic sequelae in patients with T2DM. We searched PubMed, MEDLINE, and Google Scholar databases for recently included agents and novel medication under development for treatment of T2DM. We discuss the pathophysiology of T2DM and review how the emerging anti-diabetic agents target the metabolic pathways involved. We also look at some of the limiting factors to developing new medication and the introduction of unique methods, including facilitating drug delivery to bypass some of these obstacles. However, despite the advances in the therapeutic options for the treatment of T2DM in recent years, the industry still lacks a curative agent. |
| first_indexed | 2024-12-16T23:42:48Z |
| format | Article |
| id | doaj.art-fd2cb2a986f144a2b4b91b4c3fec350e |
| institution | Directory Open Access Journal |
| issn | 2042-0196 |
| language | English |
| last_indexed | 2024-12-16T23:42:48Z |
| publishDate | 2021-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Endocrinology and Metabolism |
| spelling | doaj.art-fd2cb2a986f144a2b4b91b4c3fec350e2022-12-21T22:11:34ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01962021-09-011210.1177/20420188211042145Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practiceNajeeb ShahMohammed Altigani AbdallaHarshal DeshmukhThozhukat SathyapalanDiabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant physical and psychological detriment to patients. As of 2019, 463 million people are estimated to be living with DM worldwide, out of which 90% have type-2 diabetes mellitus (T2DM). Over the years, significant progress has been made in identifying the risk factors for developing T2DM, understanding its pathophysiology and uncovering various metabolic pathways implicated in the disease process. This has culminated in the implementation of robust prevention programmes and the development of effective pharmacological agents, which have had a favourable impact on the management of T2DM in recent times. Despite these advances, the incidence and prevalence of T2DM continue to rise. Continuing research in improving efficacy, potency, delivery and reducing the adverse effect profile of currently available formulations is required to keep pace with this growing health challenge. Moreover, new metabolic pathways need to be targeted to produce novel pharmacotherapy to restore glucose homeostasis and address metabolic sequelae in patients with T2DM. We searched PubMed, MEDLINE, and Google Scholar databases for recently included agents and novel medication under development for treatment of T2DM. We discuss the pathophysiology of T2DM and review how the emerging anti-diabetic agents target the metabolic pathways involved. We also look at some of the limiting factors to developing new medication and the introduction of unique methods, including facilitating drug delivery to bypass some of these obstacles. However, despite the advances in the therapeutic options for the treatment of T2DM in recent years, the industry still lacks a curative agent.https://doi.org/10.1177/20420188211042145 |
| spellingShingle | Najeeb Shah Mohammed Altigani Abdalla Harshal Deshmukh Thozhukat Sathyapalan Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice Therapeutic Advances in Endocrinology and Metabolism |
| title | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice |
| title_full | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice |
| title_fullStr | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice |
| title_full_unstemmed | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice |
| title_short | Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice |
| title_sort | therapeutics for type 2 diabetes mellitus a glance at the recent inclusions and novel agents under development for use in clinical practice |
| url | https://doi.org/10.1177/20420188211042145 |
| work_keys_str_mv | AT najeebshah therapeuticsfortype2diabetesmellitusaglanceattherecentinclusionsandnovelagentsunderdevelopmentforuseinclinicalpractice AT mohammedaltiganiabdalla therapeuticsfortype2diabetesmellitusaglanceattherecentinclusionsandnovelagentsunderdevelopmentforuseinclinicalpractice AT harshaldeshmukh therapeuticsfortype2diabetesmellitusaglanceattherecentinclusionsandnovelagentsunderdevelopmentforuseinclinicalpractice AT thozhukatsathyapalan therapeuticsfortype2diabetesmellitusaglanceattherecentinclusionsandnovelagentsunderdevelopmentforuseinclinicalpractice |